StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) from a sell rating to a hold rating in a research report report published on Monday.
A number of other equities research analysts also recently issued reports on ABEO. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $17.50.
Read Our Latest Report on ABEO
Abeona Therapeutics Stock Performance
Shares of ABEO stock traded down $0.07 on Monday, reaching $4.97. The stock had a trading volume of 529,297 shares, compared to its average volume of 407,720. The stock has a market cap of $216.05 million, a P/E ratio of -1.85 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.45. The company has a 50 day simple moving average of $5.42 and a 200 day simple moving average of $5.81.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19. Equities research analysts expect that Abeona Therapeutics will post -1.16 EPS for the current year.
Institutional Investors Weigh In On Abeona Therapeutics
A number of institutional investors have recently bought and sold shares of ABEO. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics in the fourth quarter worth about $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics in the 4th quarter worth approximately $67,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at approximately $84,000. Oxford Asset Management LLP bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics in the third quarter worth $151,000. Hedge funds and other institutional investors own 80.56% of the company's stock.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
